⚲
|
Charles River Laboratories International Inc | |
---|---|
Ticker | CRL |
CIK # | 0001100682 |
CUSIP | 159864107 |
Sector | Trade & Services |
Industry | Services-Commercial Physical & Biological Research |
Phone | 9786586000 |
Address | 261 Ballardvale Street Wilmington, MA 01867 |
Source | [EDGAR] |
Market Cap, 13F ($) |
---|
Business |
---|
We are a full service, early-stage contract research organization (CRO). We have built upon our original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, which is able to support our clients from target identification through non-clinical development. We also provide a suite of products and services to support our clients' manufacturing activities. Utilizing our broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness and increases speed to market. The development of new drugs requires a steadily increasing investment of time and money. Various studies and reports estimate that it takes between 10 to 15 years, up to $2.0 billion excluding time costs and exploration of between 10,000 and 15,000 drug molecules to produce a single Food and Drug Administration (FDA)-approved drug. Discovery represents the earliest stages of research in the life sciences, directed at the identification, screening, and selection of a lead molecule for future drug development. Discovery activities typically extend anywhere from 4 to 6 years in conventional pharmaceutical research and development (R&D) timelines. |
CIK | Filing | 2011 - 2023 |
---|---|---|
[0001100682] | 10-K | |
[0001100682] | 10-Q | |
[0001100682] | 3 | |
[0001100682] | 4 | |
[0001100682] | 5 | |
[0001100682] | 8-K | |
[0001100682] | SC 13G |